Cardio-oncology & otherRandomised controlled trial
Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapy
- Non-randomised clinical trial
- single-group
Authors' conclusion
Reduced CTRCD surveillance every 6 months is safe and feasible for patients at low risk for CTRCD
Study context
- Population
- Patients with HER2-positive breast cancer treated with non-anthracycline HER2-targeted therapy; excluded: previous anthracycline exposure, significant CVD, uncontrolled hypertension
- Participants
- 190 patients
- Comparison
- Reduced cancer therapy-related cardiac dysfunction (CTRCD) surveillance (echocardiography every 6 months) during non-anthracycline HER2-targeted therapy
- Primary endpoint
- Cardiac event rate:
- HF
- CV death
- Follow-up
- 1 year
Primary result
As reported in the abstract
Cardiac events:
- HF
- CV death
Cardiac events
0 (0%; 1-sided 97.5% CI: 0%-1.9%)
Secondary outcomes
Asymptomatic CTRCD
- Asymptomatic CTRCD, 1 patient; resumed therapy after temporary treatment interruption
- 0.5%; 95% CI: 0.01%-2.9%
Adherence to reduced surveillance schedule every 6 months
- Adherence, ITT
- 73.2%
- Adherence, per-protocol
- 79.9%
Original publication
Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapy. JACC CardioOncol. doi:10.1016/j.jaccao.2025.05.006
Summarised from the published abstract; every number is checked against it